6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride

We are 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride CAS: 84163-13-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:    6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride
CAS.NO:  84163-13-3
Synonyms:
6-fluoro-3-piperidin-4-yl-1,2-benzoxazole,hydrochloride
6-Fluor-3-(piperidin-4-yl)-1,2-benzisoxazolhydrochlorid

Molecular Formula: C12H14ClFN2O
Molecular Weight:   256.70400

Physical and Chemical Properties:
Density: /
Boiling point: 387.3ºC at 760 mmHg
Melting point: /
Flash point: 188ºC
Refractive index: /

Specification:
Appearance:White crystalline powder
Purity:≥99.0%
LOSS ON DRYING:Not more than 0.5%(w/w)
RELATEDSUBSTANCES(By HPLC)
IMPURITY-A, AT RRT ABOUT 0.59: Not more than 0.2%
SINGLE MAXIMUM IMPURITY: Not more than 0.2%
TOTAL IMPURITIES: Not more than0.5%
RESIDUE ON IGNITION:Not more than 0.2%

 

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
Intermediates of Risperidone CAS: 106266-06-2.

Related News: The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.4-Bromo-3-(trifluoromethyl)aniline With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.92592-02-4 With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.Ácido Elaidico CAS:112-79-8 The company’s short-term plan is to move from a purely chemical intermediate manufacturer to a formula active material supplier, and its long-term goal is to become a solution provider in the selected segment. In the future, this business is expected to become a new growth point for the company’s profit.The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries.